Absolute Antibody

Executive Summary

Absolute Antibody is a UK-based biotechnology company specializing in the production and engineering of recombinant antibodies. Founded in 2012 and headquartered in Oxford, the company provides high-quality, sequence-defined antibodies and custom engineering services for research, diagnostic, and therapeutic applications. Leveraging proprietary platforms, Absolute Antibody offers species-engineered, chimeric, and humanized antibodies with precise specificity, addressing the growing demand for reproducible and scalable antibody reagents. As a private company, it serves a global clientele in academia and pharma, and its technology is critical for advancing precision medicine and biotherapeutic development. The company's focus on recombinant antibodies positions it well in a market increasingly shifting away from traditional monoclonal antibodies due to issues with batch-to-batch variability. While financial details are not publicly disclosed, Absolute Antibody's niche expertise and established presence in the UK biotech ecosystem suggest a stable growth trajectory. However, the competitive landscape includes established players like Abcam and Thermo Fisher, requiring continuous innovation and strategic partnerships to maintain market share.

Upcoming Catalysts (preview)

• TBDStrategic partnership with a major pharma for therapeutic antibody development50% success
• Q3 2026Launch of a new recombinant antibody catalog targeting emerging biomarkers70% success
• Q4 2026Series B or later-stage funding round to scale manufacturing and expand into North America40% success